Company Overview and News

 
Appendix 4C - quarterly

2016-04-29 asx.com.au

 
Half Yearly Report and Accounts

2016-02-26 asx.com.au

 
AllianceBernstein Holding's (AB) CEO Peter Kraus on Q4 2015 Results - Earnings Call Transcript

2016-02-11 seekingalpha
AllianceBernstein Holding LP (NYSE:AB) Q4 2015 Earnings Call February 11, 2016 8:00 AM ET Executives Andrea Prochniak - Head, Investor Relations Peter Kraus - C

 
Appendix 4C - quarterly

2016-01-29 asx.com.au

 
Results of Annual General Meeting

2015-11-27 asx.com.au

 
Appendix 4C - quarterly

2015-10-30 asx.com.au

 
Annual Report to shareholders

2015-10-23 asx.com.au

 
Royal Bank Of Canada Form 424B2 (Prospectus)

2015-10-02 sec.gov
l101150424b2.htm     September 2015 MSELN-183-C Registration Statement No. 333-203433 PRICING SUPPLEMENT Dated September 30, 2015 Filed Pursuant to Rule 424(b)(2)   STRUCTURED INVESTMENTS Opportunities in International Equities   $4,257,940 PLUS Based on the Performance of the WisdomTree® Japan Hedged Equity Fund, due January 5, 2017 Performance Leveraged Upside SecuritiesSM Principal at Risk Securities The PLUS are unsubordinated unsecured obligations of Royal Bank of Canada, do not pay interes

 
Royal Bank Of Canada Form 424B2 (Prospectus)

2015-10-02 sec.gov
n1011150434b2.htm        September 2015 MSELN-185-C Registration Statement No. 333-203433 PRICING SUPPLEMENT Dated September 30, 2015 Filed Pursuant to Rule 424(b)(2) STRUCTURED INVESTMENTS Opportunities in U.S. and International Equities $4,524,200 Autocallable Buffered PLUS Based on a Basket of Three Equity Indices due October 3, 2018 Autocallable Buffered Performance Leveraged Upside SecuritiesSM Principal at Risk Securities The Autocallable Buffered PLUS (the “securities,” or the “Buffered P

 
Morgan Stanley Form FWP

2015-10-02 sec.gov
    October 2015 Preliminary Terms No. 603 Registration Statement No. 333-200365 Dated October 1, 2015 Filed pursuant to Rule 433 Structured Investments Opportunities in International Equities    Buffered PLUS Based on the Value of the EURO STOXX 50® Index due November 2, 2018 Buffered Performance Leveraged Upside SecuritiesSM  Principal at Risk Securities  The Buffered PLUS offered are unsecured obligations of Morgan Stanley, will pay no interest, provide a minimum payment at maturity of only 1

 
Morgan Stanley Form FWP

2015-10-02 sec.gov
  October 2015 Preliminary Terms No. 605 Registration Statement No. 333-200365 Dated October 1, 2015 Filed pursuant to Rule 433 Structured Investments Opportunities in International Equities  Enhanced Trigger Jump Securities Based on the Value of the EURO STOXX 50® Index due November 4, 2021 Principal at Risk Securities  Enhanced Trigger Jump Securities, which we refer to as the securities, will pay an amount in cash at maturity that may be greater than or less than the stated principal amount d

 
Morgan Stanley Form FWP

2015-10-02 sec.gov
  September 2015   Pricing Sheet dated September 30, 2015 relating to Preliminary Terms No. 568 dated September 18, 2015 Registration Statement No. 333-200365 Filed pursuant to Rule 433 Structured Investments  Opportunities in International Equities   Enhanced Trigger Jump Securities Based on the Value of the EURO STOXX 50® Index due October 5, 2021 Principal at Risk Securities PRICING TERMS – SEPTEMBER 30, 2015 Issuer: Morgan Stanley Aggregate principal amount: $2,705,000 Stated principal amoun

 
Morgan Stanley Form 424B2 (Prospectus)

2015-10-02 sec.gov
CALCULATION OF REGISTRATION FEE       Maximum Aggregate   Amount of Registration Title of Each Class of Securities Offered   Offering Price   Fee Securities due 2020   $3,441,000   $346.51     September 2015 Pricing Supplement No. 533 Registration Statement No. 333-200365 Dated September 30, 2015 Filed pursuant to Rule 424(b)(2) Structured Investments Opportunities in U.S. and International Equities and Commodities Securities Linked to an ETF Basket due April 6, 2020—Leveraged Upside Participati

 
Annual Report

2015-09-30 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...